Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G, Di Renzo N, Cascavilla N, Carella AM, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Merchionne F, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rossini B, Spina A, Sgherza N, Specchia G, Musto P, Pastore D.
Mele G, et al. Among authors: di renzo n.
Leuk Lymphoma. 2023 Oct;64(10):1715-1718. doi: 10.1080/10428194.2023.2232487. Epub 2023 Jul 7.
Leuk Lymphoma. 2023.
PMID: 37417467
No abstract available.